ArticleAnnals of African medicine2026
A Comparative Study between Serum Cystatin C and Microalbuminuria in the Diagnosis of Nephropathy in Type 2 Diabetes Mellitus.
Article in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy is the most serious complication associated with diabetes mellitus and the diagnosis typically relies on the identification of albuminuria. However, there are cases of renal insufficiency without albuminuria reported in diabetic patients. This study aimed to evaluate the association between microalbuminuria and serum cystatin C, as well as to assess the clinical usefulness of cystatin C in predicting the renal impairment in diabetic patients. MATERIALS AND
methodsIt was a cross-sectional study conducted on type 2 diabetic patients and healthy controls, who were categorized into four groups based on their albuminuria levels. All the participants were investigated for serum cystatin C, albuminuria, and traditional markers of nephropathy.
resultsThe level of cystatin C was significantly elevated in diabetic patients as compared to healthy individuals. The mean ± standard deviation progressively raised among the normoalbuminuric diabetic patients (1.32 ± 0.32 mg/L) and reached the peak in nephropathy patients (1.86 ± 0.25 mg/L). There was a significant positive correlation of cystatin C with albuminuria ( P < 0.001). Receiver operating characteristic analysis of cystatin C showed an area under the curve of 0.881 (95% confidence interval, 0.832-0.930) with a sensitivity of 80.83% and a specificity of 86.67%, demonstrating the diagnostic efficacy of cystatin C ( P < 0.001).
conclusionElevated serum cystatin C level was observed in type 2 diabetic patients before the development of notable albuminuria, and its concentration rises as nephropathy advances, indicating that cystatin C could serve as a potential and earlier marker of renal dysfunction compared to albuminuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.